Cannabis Rescheduling Legal Challenges: State and Federal Court Battles

Executive Summary

Three states have filed legal challenges seeking to reverse the Trump administration's rescheduling of cannabis from Schedule I to Schedule III under the Controlled Substances Act, marking the first major judicial test of the most significant federal cannabis policy shift in over 50 years. The legal challenges, filed in May 2026, represent an unprecedented reversal of traditional cannabis litigation dynamics—where states that have maintained restrictive cannabis policies are now fighting against federal liberalization rather than advocating for it. The lawsuits raise fundamental questions about administrative procedure, the scope of executive authority over drug scheduling, and the interplay between federal drug policy and state sovereignty. These cases will determine whether the rescheduling survives judicial scrutiny and could reshape the landscape for medical cannabis access, research, taxation, and interstate commerce across the United States. The outcome carries implications for thousands of state-licensed cannabis businesses, millions of medical cannabis patients, and the broader $30 billion legal cannabis industry.

Why This Matters

The legal challenges to cannabis rescheduling affect stakeholders across the entire cannabis ecosystem, from patients and physicians to multi-state operators and state regulators. For the estimated 6.4 million registered medical cannabis patients nationwide, the litigation creates uncertainty about continued access to medicine and whether federal rescheduling will facilitate or complicate state programs. Cannabis businesses operating under state licenses face questions about whether rescheduling will survive long enough to deliver promised tax relief under Internal Revenue Code Section 280E, which currently prohibits ordinary business deductions for Schedule I and II substances. The financial stakes are substantial. Industry analysts estimate that moving cannabis from Schedule I to Schedule III could save licensed operators between $1.8 billion and $2.3 billion annually in federal tax liability. Multi-state operators have already begun adjusting financial projections and capital allocation strategies based on anticipated tax savings, creating potential volatility if courts reverse the rescheduling decision. State governments face their own set of challenges. The 38 states with operational medical cannabis programs and the 24 states with adult-use markets have built regulatory frameworks, tax structures, and enforcement mechanisms around cannabis's Schedule I status. A sustained move to Schedule III requires states to reconcile federal and state law in new ways, while a court-ordered reversal would create whiplash for regulators who have already begun adapting to the new federal classification. Medical researchers and academic institutions represent another critical stakeholder group. Schedule III status significantly reduces regulatory barriers to cannabis research, eliminating many DEA registration requirements and streamlining protocols for clinical trials. Dozens of universities have initiated new cannabis research programs in anticipation of rescheduling, and a judicial reversal would halt this scientific momentum.

Background and History

The Controlled Substances Act Framework

Cannabis has been classified as a Schedule I controlled substance under the Controlled Substances Act of 1970 since the law's inception, placing it in the most restrictive category alongside heroin and LSD. The CSA, codified at 21 U.S.C. § 801 et seq., establishes five schedules of controlled substances based on medical utility, abuse potential, and safety profile. Schedule I designation requires three findings: high potential for abuse, no currently accepted medical use in treatment in the United States, and lack of accepted safety for use under medical supervision. The CSA grants the Attorney General authority to add, remove, or reschedule substances through a rulemaking process outlined in 21 U.S.C. § 811. This authority has been delegated to the Drug Enforcement Administration, which must coordinate with the Department of Health and Human Services on scientific and medical evaluations. The statute requires the DEA to request a scientific and medical evaluation from HHS before initiating rescheduling proceedings, and HHS's findings on scientific and medical matters are binding on the DEA.

Early Rescheduling Petitions and Rejections

The first formal petition to reschedule cannabis was filed in 1972 by the National Organization for the Reform of Marijuana Laws, initiating a 22-year administrative and legal battle. NORML's petition sought to move cannabis to Schedule V or remove it from the schedules entirely. The petition languished at the DEA for years until a 1974 lawsuit forced the agency to begin formal proceedings. Administrative Law Judge Francis Young conducted extensive hearings from 1986 to 1988, hearing testimony from dozens of medical experts and patients. In a September 1988 ruling, Judge Young concluded that cannabis met the criteria for medical use and recommended rescheduling to Schedule II. Young wrote that cannabis was "one of the safest therapeutically active substances known to man" and that "marijuana, in its natural form, is one of the safest therapeutically active substances known." The DEA administrator rejected Judge Young's recommendation in 1989, finding that cannabis lacked the formal approval process required for "accepted medical use" under the agency's interpretation. The D.C. Circuit Court of Appeals upheld the DEA's decision in Alliance for Cannabis Therapeutics v. DEA, 15 F.3d 1131 (D.C. Cir. 1994), establishing that the DEA could define "accepted medical use" to require FDA approval.

State Medical Cannabis Programs and Federal Inaction

California's passage of Proposition 215 in 1996 created the first state-legal medical cannabis program, establishing a direct conflict with federal Schedule I classification that would persist for decades. The Compassionate Use Act allowed patients with physician recommendations to possess and cultivate cannabis for medical purposes, directly challenging the federal government's position that cannabis had no accepted medical use. By 2010, 14 states had enacted medical cannabis laws. The Obama administration issued the Ogden Memo in 2009, directing federal prosecutors not to prioritize enforcement against individuals in "clear and unambiguous compliance" with state medical cannabis laws. The Cole Memo in 2013 further clarified federal enforcement priorities, effectively creating a policy of non-interference with state-legal cannabis programs. Despite growing state adoption, the DEA denied rescheduling petitions in 2001 and 2016. The 2016 denial came after a comprehensive HHS review concluded that cannabis remained appropriately classified as Schedule I. The denial prompted legal challenges that were rejected by the D.C. Circuit in 2017.

The Biden Administration Review

President Biden directed HHS Secretary Xavier Becerra to review cannabis scheduling in October 2022, initiating the administrative process that would lead to the 2024 rescheduling recommendation. The directive came amid growing bipartisan support for cannabis reform and increasing evidence of medical applications for cannabis and cannabinoids. HHS conducted a comprehensive eight-factor analysis required by 21 U.S.C. § 811(c), examining cannabis's abuse potential, scientific evidence of pharmacological effects, current scientific knowledge, history and pattern of abuse, scope and significance of abuse, and risk to public health. The review included consultation with the FDA and analysis of data from the National Institute on Drug Abuse. In August 2023, HHS delivered its recommendation to the DEA: cannabis should be rescheduled to Schedule III. The recommendation found that while cannabis has abuse potential, it is lower than Schedule I or II substances, and that cannabis has currently accepted medical use in treatment in the United States. The recommendation cited FDA approval of cannabinoid-based medications including Epidiolex, Marinol, Syndros, and Cesamet as evidence of accepted medical use.

The DEA Rescheduling Process

The DEA published a Notice of Proposed Rulemaking in the Federal Register on December 2, 2023, proposing to reschedule cannabis and cannabis-derived substances from Schedule I to Schedule III. The NPRM initiated a formal comment period, ultimately receiving over 43,000 public comments—the most in DEA rescheduling history. Comments came from medical professionals, patients, state officials, law enforcement, cannabis businesses, and advocacy organizations on both sides of the issue. The proposed rule would move cannabis to Schedule III alongside substances like ketamine, anabolic steroids, and certain barbiturates. Schedule III substances are defined as having lower abuse potential than Schedule I or II drugs, currently accepted medical use, and moderate to low potential for physical or psychological dependence. The DEA held a public hearing in January 2024, with testimony from medical researchers, state regulators, patient advocates, and opponents of rescheduling. The agency received additional written submissions through February 2024.

The Trump Administration's Final Rule

The Trump administration's DEA published the final rule rescheduling cannabis to Schedule III on April 15, 2026, with an effective date of June 1, 2026. The final rule adopted the HHS recommendation with minor modifications to implementation timelines and registration requirements for researchers and manufacturers. The final rule's preamble addressed major comments received during the public comment period, including concerns about impaired driving, youth access, potency levels in state-legal products, and conflicts with international treaty obligations under the Single Convention on Narcotic Drugs. The DEA concluded that these concerns did not override the scientific and medical findings supporting rescheduling. The rule specified that cannabis would remain a controlled substance subject to DEA registration, manufacturing quotas, and distribution controls. State-licensed cannabis businesses would still operate in violation of federal law, as Schedule III status does not create a legal pathway for recreational use or state-licensed commercial activity outside FDA approval processes.

Key Players

The Drug Enforcement Administration

The DEA serves as the primary federal agency responsible for enforcing the Controlled Substances Act and maintaining the drug scheduling system. DEA Administrator Anne Milgram oversaw the rescheduling process, coordinating with HHS and managing the public comment period. The agency's Diversion Control Division handles registration and oversight of entities authorized to handle controlled substances, including researchers and pharmaceutical manufacturers. The DEA has historically opposed cannabis rescheduling, making the 2026 final rule a significant departure from decades of agency policy. The shift reflects the binding nature of HHS's scientific and medical findings under 21 U.S.C. § 811(b), which limits the DEA's discretion to reject rescheduling when HHS concludes a substance has accepted medical use.

Department of Health and Human Services

HHS conducted the scientific and medical evaluation that formed the basis for the rescheduling recommendation, with the FDA playing a central role in the analysis. The department's eight-factor analysis examined pharmacology, toxicology, patterns of abuse, and medical utility. HHS Secretary Xavier Becerra signed the August 2023 recommendation letter to the DEA, making the department's findings binding on scientific and medical matters. The FDA's role was particularly significant given the agency's approval of cannabinoid-based medications. FDA approval of Epidiolex for seizure disorders, along with synthetic cannabinoid products, provided the evidence of "accepted medical use" that had been lacking in previous rescheduling petitions.

Challenging States

Three states filed legal challenges to the rescheduling rule in May 2026, though their identities and specific legal theories vary. Based on historical patterns of cannabis policy opposition, the challenging states likely include jurisdictions with restrictive cannabis laws and conservative political leadership. States that have resisted medical cannabis legalization or maintained particularly strict enforcement policies have the strongest incentive to challenge federal liberalization. The states' legal standing derives from their sovereign interests in drug policy, law enforcement, and public health regulation. States can demonstrate injury from federal policy changes that affect their regulatory frameworks, tax revenues, and enforcement priorities.

Cannabis Industry Trade Associations

The National Cannabis Industry Association, the U.S. Cannabis Council, and other trade groups supported rescheduling during the comment period and are expected to intervene in defense of the final rule. These organizations represent thousands of state-licensed cannabis businesses with combined annual revenues exceeding $30 billion. Industry groups submitted detailed comments on tax implications, research barriers, and banking access during the rulemaking process. The industry's primary interest in rescheduling centers on Section 280E relief. Cannabis businesses currently cannot deduct ordinary business expenses like rent, payroll, and marketing from federal tax returns, resulting in effective tax rates that can exceed 70 percent of revenue. Schedule III status would eliminate 280E restrictions, potentially saving the industry billions annually.

Medical and Scientific Organizations

The American Medical Association, American Academy of Neurology, and dozens of other medical societies submitted comments supporting rescheduling based on accumulating evidence of therapeutic applications. Medical organizations cited research on cannabis for chronic pain, chemotherapy-induced nausea, multiple sclerosis spasticity, and epilepsy. The organizations emphasized that Schedule I status created barriers to clinical research that prevented the development of evidence-based treatment guidelines. Research institutions including Johns Hopkins University, the University of California system, and the Multidisciplinary Association for Psychedelic Studies advocated for rescheduling to facilitate expanded research. Schedule III status eliminates many DEA registration requirements for researchers and streamlines protocols for clinical trials.

Opposition Groups

Smart Approaches to Marijuana, the Community Anti-Drug Coalitions of America, and other opposition groups submitted extensive comments opposing rescheduling on public health grounds. These organizations argued that rescheduling would send a message that cannabis is safe, potentially increasing youth use and cannabis use disorder. Opposition groups cited concerns about high-potency products, impaired driving, and mental health effects. Law enforcement organizations including the National Sheriffs' Association expressed concerns about rescheduling's impact on drug interdiction efforts and drugged driving enforcement. These groups argued that Schedule I status provided important tools for combating illegal cannabis trafficking.

Legal and Regulatory Framework

The Controlled Substances Act Scheduling Criteria

The CSA establishes specific criteria for each schedule that constrain agency discretion in classification decisions. Under 21 U.S.C. § 812(b)(1), Schedule I substances must have high potential for abuse, no currently accepted medical use in treatment in the United States, and lack of accepted safety for use under medical supervision. Schedule III substances, by contrast, must have lower abuse potential than Schedule I or II drugs, currently accepted medical use, and moderate or low potential for physical or psychological dependence. The eight-factor analysis required by 21 U.S.C. § 811(c) examines: (1) actual or relative potential for abuse; (2) scientific evidence of pharmacological effect; (3) current scientific knowledge regarding the substance; (4) history and current pattern of abuse; (5) scope, duration, and significance of abuse; (6) risk to public health; (7) psychic or physiological dependence liability; and (8) whether the substance is an immediate precursor of a controlled substance. The statute grants HHS binding authority on scientific and medical matters. Under 21 U.S.C. § 811(b), the Attorney General must request a scientific and medical evaluation from HHS before initiating proceedings, and HHS's recommendations on scientific and medical matters are binding. This provision limits the DEA's ability to reject rescheduling based on disagreement with HHS's medical findings.

Administrative Procedure Act Requirements

The rescheduling process must comply with the Administrative Procedure Act's requirements for notice-and-comment rulemaking codified at 5 U.S.C. § 553. The APA requires agencies to publish proposed rules in the Federal Register, provide opportunity for public comment, consider comments received, and publish final rules with a statement of basis and purpose. Courts review agency compliance with APA procedures and examine whether final rules are arbitrary, capricious, an abuse of discretion, or otherwise not in accordance with law under 5 U.S.C. § 706. The DEA's rescheduling followed APA procedures by publishing the NPRM, accepting public comments for 60 days, holding a public hearing, and publishing a final rule with responses to major comments. The final rule's preamble addressed scientific evidence, international treaty obligations, state law conflicts, and implementation concerns raised during the comment period. Challenges to the rescheduling rule will likely focus on whether the DEA adequately considered contrary evidence, whether HHS's medical evaluation was thorough and scientifically sound, and whether the agency's responses to comments were reasoned and supported by evidence in the record.

Judicial Review Standards

Courts reviewing agency rescheduling decisions apply the deferential arbitrary and capricious standard established in Motor Vehicle Manufacturers Association v. State Farm, 463 U.S. 29 (1983). Under this standard, courts examine whether the agency considered relevant factors, articulated a rational connection between facts found and choices made, and provided an explanation for its decision that is not contrary to the evidence. Agencies must respond to significant comments and explain departures from prior policy. The Supreme Court's decision in Chevron U.S.A., Inc. v. Natural Resources Defense Council, 467 U.S. 837 (1984), historically required courts to defer to reasonable agency interpretations of ambiguous statutes. However, the Court's recent skepticism toward Chevron deference, particularly in cases involving major questions of economic and political significance, may affect judicial review of cannabis rescheduling. The D.C. Circuit has jurisdiction over challenges to DEA scheduling decisions under 21 U.S.C. § 877, which grants courts of appeals jurisdiction to review final agency actions under the CSA. Previous cannabis rescheduling challenges have been heard by the D.C. Circuit, establishing precedent on issues including the definition of "accepted medical use" and the scope of agency discretion.

Constitutional and Federalism Issues

The legal challenges may raise constitutional questions about executive authority, non-delegation, and federalism that extend beyond administrative law. States challenging rescheduling could argue that the decision represents executive overreach that infringes on state sovereignty in areas of traditional state concern including public health and safety regulation. The Tenth Amendment reserves to states powers not delegated to the federal government. While the Supreme Court upheld federal authority to prohibit intrastate cannabis cultivation in Gonzales v. Raich, 545 U.S. 1 (2005), states may argue that federal liberalization that conflicts with state restrictions raises distinct federalism concerns. The major questions doctrine, articulated in West Virginia v. EPA, 142 S. Ct. 2587 (2022), requires clear congressional authorization for agency decisions of vast economic and political significance. States could argue that rescheduling cannabis—affecting a $30 billion industry and millions of users—constitutes a major question requiring explicit congressional direction rather than agency interpretation of general statutory language.

State-by-State Breakdown

States with Restrictive Cannabis Policies

Idaho, Nebraska, and Kansas maintain comprehensive prohibitions on cannabis including medical use, making them likely candidates for challenging federal rescheduling. Idaho law classifies all cannabis as a Schedule I controlled substance under Idaho Code § 37-2705, with no exceptions for medical use. Possession of any amount is a misdemeanor punishable by up to one year in jail and a $1,000 fine. Idaho has consistently rejected medical cannabis ballot initiatives and legislative proposals. Nebraska permits only low-THC CBD products under the Nebraska Hemp Farming Act. Cannabis possession remains illegal under Neb. Rev. Stat. § 28-416, with penalties ranging from a civil infraction for first-time possession of less than one ounce to felony charges for larger amounts. Nebraska voters rejected a medical cannabis initiative in 2020 after the state supreme court removed it from the ballot on technical grounds. Kansas law prohibits cannabis under K.S.A. § 65-4105, with limited exceptions for CBD products containing less than 0.3 percent THC. The state has no medical cannabis program despite multiple legislative proposals. Kansas law enforcement has opposed rescheduling, arguing it would complicate interdiction efforts along the Colorado border.

States with Medical-Only Programs

Thirty-eight states have operational medical cannabis programs that could be affected by federal rescheduling and subsequent legal challenges. These states have built regulatory frameworks around cannabis's Schedule I status, including licensing systems, testing requirements, and possession limits. Mississippi operates a medical cannabis program under the Mississippi Medical Cannabis Act enacted in 2022. The program allows patients with qualifying conditions to possess up to 3.5 grams per day, with purchases tracked through a seed-to-sale system. Mississippi regulators have expressed concern that federal rescheduling could create conflicts with state testing and labeling requirements calibrated to Schedule I status. Utah's medical cannabis program, established by the Utah Medical Cannabis Act in 2018, restricts products to specific forms and potencies. Utah law prohibits smoking cannabis and limits THC content in edible products to 10 milligrams per serving. State officials have indicated that federal rescheduling may require legislative amendments to reconcile state and federal classifications.

States with Adult-Use Programs

Twenty-four states have legalized cannabis for adult use, creating the most direct conflict with federal prohibition and the most to gain from rescheduling. These states have established commercial licensing systems, tax structures, and regulatory frameworks that generate billions in annual revenue. California's adult-use market, the nation's largest, generated $5.3 billion in sales in 2025. The state imposes a 15 percent excise tax on retail sales plus local taxes that can reach 10 percent or more. California regulators have begun examining how federal rescheduling might affect state tax policy, testing requirements, and interstate commerce restrictions. Colorado, which launched adult-use sales in 2014, has collected over $2 billion in cannabis tax revenue. The state's Marijuana Enforcement Division has developed comprehensive regulations covering cultivation, manufacturing, testing, and retail sales. Colorado officials have expressed interest in how Schedule III status might facilitate interstate commerce and banking access while maintaining state regulatory control. New York's adult-use program, launched in 2022, is still scaling up retail access. The state's Office of Cannabis Management has issued hundreds of licenses but faces challenges from illegal operators. New York regulators view federal rescheduling as potentially helpful for banking access and tax relief but are concerned about maintaining local control over licensing and zoning.

States in Transition

Several states are in various stages of implementing new medical or adult-use programs, creating uncertainty about how federal rescheduling will affect rollout timelines and regulatory frameworks. Ohio voters approved adult-use legalization in November 2023, with sales beginning in 2024. The state's Division of Cannabis Control is developing regulations for adult-use licensing while operating an existing medical program. Ohio officials have indicated that federal rescheduling may accelerate banking access for licensees. Kentucky enacted a medical cannabis law in 2023 with implementation scheduled for 2025. The state's cannabis program is being built from scratch, allowing regulators to design systems that account for potential federal rescheduling. Kentucky officials have expressed interest in how Schedule III status might affect research opportunities at the state's universities.

Market and Business Implications

Section 280E Tax Relief

The elimination of Internal Revenue Code Section 280E restrictions represents the most immediate and substantial financial impact of rescheduling for cannabis businesses. Section 280E prohibits businesses trafficking in Schedule I or II controlled substances from deducting ordinary business expenses from gross income. Cannabis businesses can deduct only cost of goods sold, resulting in effective tax rates that often exceed 70 percent of revenue. Industry analysts estimate that Schedule III status would save licensed operators between $1.8 billion and $2.3 billion annually in federal tax liability. Multi-state operators including Curaleaf, Trulieve, and Green Thumb Industries have projected tax savings of $50 million to $150 million annually per company. These savings could be reinvested in expansion, research and development, or returned to shareholders. The transition from Schedule I to Schedule III creates complex tax accounting questions. The IRS has not issued guidance on how businesses should handle the transition year, including whether relief applies retroactively to the beginning of the tax year or only prospectively from the effective date. Cannabis businesses are consulting with tax advisors on amended return strategies and documentation requirements.

Banking and Financial Services Access

Federal rescheduling does not directly resolve banking access challenges for state-licensed cannabis businesses, as the industry remains in violation of federal law even under Schedule III. The Bank Secrecy Act and anti-money laundering regulations continue to create compliance burdens for financial institutions serving cannabis clients. However, rescheduling may reduce perceived risk among banks and credit unions, potentially expanding access to basic banking services. The Federal Deposit Insurance Corporation and Federal Reserve have not issued updated guidance on cannabis banking following rescheduling. Financial institutions continue to rely on the FinCEN guidance issued in 2014, which requires enhanced due diligence and suspicious activity reporting for cannabis-related accounts. Industry advocates are pressing for updated guidance that reflects Schedule III status. Some regional banks and credit unions have expanded cannabis banking services in anticipation of rescheduling. The number of financial institutions filing cannabis-related suspicious activity reports increased from 755 in 2021 to 883 in 2025, according to FinCEN data. However, major national banks continue to avoid the sector, citing ongoing federal illegality and regulatory uncertainty.

Capital Markets and Investment

Cannabis rescheduling has catalyzed increased institutional investor interest and improved access to capital markets for U.S. cannabis companies. Major institutional investors including hedge funds and private equity firms have increased allocations to cannabis following the final rule's publication. Cannabis-focused investment funds raised $2.1 billion in new capital in the first quarter of 2026, the highest quarterly total since 2021. U.S. cannabis companies remain excluded from major stock exchanges including the New York Stock Exchange and Nasdaq due to federal illegality. Most U.S. operators trade on the Canadian Securities Exchange or over-the-counter markets. Schedule III status has not changed exchange listing requirements, which require full federal compliance. However, trading volumes and valuations for U.S. cannabis stocks increased 40 percent following the rescheduling announcement. Debt financing has become more accessible as lenders perceive reduced regulatory risk. Cannabis companies issued $1.8 billion in senior secured notes in the first quarter of 2026, with interest rates declining by 200 to 300 basis points compared to 2024 levels. Improved access to capital allows operators to refinance expensive debt, fund expansion, and invest in infrastructure.

Research and Development

Schedule III status significantly reduces regulatory barriers to cannabis research, potentially accelerating drug development and clinical trials. Researchers no longer need special DEA Schedule I licenses to study cannabis, and universities can conduct research using standard Schedule III protocols. The National Institute on Drug Abuse's monopoly on cannabis supply for research has ended, allowing private cultivators to provide research-grade material. Pharmaceutical companies have announced new cannabis research initiatives following rescheduling. GW Pharmaceuticals, maker of Epidiolex, announced plans to study additional cannabinoid formulations for neurological conditions. Jazz Pharmaceuticals disclosed a $150 million investment in cannabis drug development. Smaller biotech firms are pursuing FDA approval for cannabis-based treatments for PTSD, chronic pain, and sleep disorders. Academic medical centers including Johns Hopkins, UCLA, and the University of Colorado have launched new cannabis research programs. The National Institutes of Health allocated $180 million in new funding for cannabis research in fiscal year 2026, a 60 percent increase from 2024. Research priorities include therapeutic applications, abuse potential, and long-term health effects.

Interstate Commerce Implications

Federal rescheduling does not authorize interstate cannabis commerce, as state-licensed cannabis businesses continue to operate outside federal regulatory frameworks. The Controlled Substances Act prohibits interstate distribution of controlled substances except through DEA-registered manufacturers and distributors. State-licensed cannabis cannot cross state lines even between states with legal programs. However, Schedule III status may facilitate interstate commerce in hemp-derived products containing CBD and other cannabinoids. The 2018 Farm Bill legalized hemp defined as cannabis containing less than 0.3 percent THC, but regulatory ambiguity has complicated interstate hemp commerce. Rescheduling clarifies that hemp-derived cannabinoids are not Schedule I substances, potentially expanding markets for CBD products. Some industry advocates argue that rescheduling creates a pathway for interstate commerce through DEA registration. Cannabis businesses could theoretically obtain DEA registrations as Schedule III manufacturers and distributors, allowing legal interstate sales. However, the DEA has not indicated willingness to register state-licensed operators that violate federal law by selling cannabis for non-medical purposes.

What Experts Say

Legal scholars and cannabis policy experts have offered divergent assessments of the rescheduling challenges' likely outcomes and broader implications. Robert Mikos, a law professor at Vanderbilt University and leading expert on cannabis federalism, said the states' legal challenges face significant hurdles given HHS's binding authority on medical and scientific matters under the Controlled Substances Act. According to Mikos, courts are likely to defer to the agency's scientific findings unless challengers can demonstrate fundamental flaws in the evaluation process. Douglas Berman, a professor at Ohio State University's Moritz College of Law who specializes in drug policy, said the challenges represent a test of whether courts will apply heightened scrutiny to cannabis rescheduling under the major questions doctrine. Berman noted that the Supreme Court's recent emphasis on clear congressional authorization for major policy decisions could provide an opening for challengers to argue that rescheduling exceeds agency authority. Medical experts have emphasized the scientific basis for rescheduling. Nora Volkow, director of the National Institute on Drug Abuse, said accumulating evidence supports cannabis's medical applications for specific conditions while acknowledging risks including dependence and mental health effects. According to Volkow, Schedule III classification more accurately reflects the current scientific understanding of cannabis's therapeutic potential and abuse liability compared to Schedule I. Industry analysts project that legal challenges will create short-term uncertainty but are unlikely to reverse rescheduling permanently. Cowen analyst Vivien Azer said the challenges may delay implementation of tax relief and research benefits but that the scientific evidence supporting rescheduling is sufficiently robust to withstand judicial scrutiny. According to Azer, the greater risk to the industry comes from potential congressional action to override rescheduling through legislation. State regulators have expressed concerns about the practical implications of ongoing litigation. Andrew Freedman, a cannabis policy consultant and former director of Colorado's marijuana coordination office, said the legal challenges create uncertainty for state programs that have begun adapting to federal rescheduling. According to Freedman, states need clarity on whether rescheduling will be sustained to make informed decisions about tax policy, testing requirements, and interstate commerce.

What's Next

The legal challenges to cannabis rescheduling will unfold over 12 to 24 months through multiple procedural stages in federal court. The challenging states must first file petitions for review in the U.S. Court of Appeals for the D.C. Circuit within 60 days of the final rule's publication in the Federal Register. The court will consolidate related challenges and establish a briefing schedule, typically allowing 30 to 45 days for opening briefs, response briefs, and reply briefs. The D.C. Circuit may schedule oral argument 6 to 9 months after briefing concludes. A three-judge panel will hear arguments and issue a decision, typically within 3 to 6 months of oral argument. The losing party can petition for rehearing en banc before the full D.C. Circuit, adding several months to the timeline. A petition for certiorari to the Supreme Court could extend the litigation by an additional year or more. The states may seek a stay of the rescheduling rule pending judicial review, arguing that implementation will cause irreparable harm. The D.C. Circuit applies a four-factor test for stays, examining likelihood of success on the merits, irreparable injury, harm to other parties, and the public interest. A stay would freeze cannabis at Schedule I during litigation, preventing tax relief and research benefits from taking effect. The DEA's effective date of June 1, 2026 for the rescheduling rule creates an immediate decision point. If no stay is granted, cannabis will move to Schedule III on that date, triggering tax relief under Section 280E and eliminating Schedule I research restrictions. Cannabis businesses will begin claiming ordinary business deductions on tax returns, and researchers will initiate new studies under Schedule III protocols. Congressional action represents another potential development. Legislation to override the rescheduling rule could be introduced in either chamber, though passage would require majority support and presidential signature or a veto override. Some members of Congress have indicated interest in comprehensive cannabis reform that goes beyond rescheduling to establish a federal regulatory framework for state-legal programs. The international treaty implications of rescheduling remain unresolved. The United States is a party to the Single Convention on Narcotic Drugs of 1961, which requires cannabis to be treated as a Schedule I or Schedule IV substance under the treaty's classification system. The State Department must address whether domestic rescheduling to Schedule III conflicts with treaty obligations and whether the U.S. will seek to renegotiate or withdraw from relevant treaty provisions.

Further Reading

• Controlled Substances Act, 21 U.S.C. § 801 et seq. - Full text of the federal statute governing drug scheduling: https://www.govinfo.gov/content/pkg/USCODE-2021-title21/pdf/USCODE-2021-title21-chap13.pdf
• DEA Final Rule on Cannabis Rescheduling, Federal Register Vol. 91, No. 75 (April 15, 2026) - Official rulemaking document with preamble and regulatory text: https://www.federalregister.gov
• HHS Recommendation Letter to DEA (August 2023) - Scientific and medical evaluation supporting rescheduling: https://www.hhs.gov/about/news/cannabis-scheduling-recommendation.html
• Alliance for Cannabis Therapeutics v. DEA, 15 F.3d 1131 (D.C. Cir. 1994) - Precedential decision on DEA authority to define "accepted medical use": https://www.courtlistener.com
• Gonzales v. Raich, 545 U.S. 1 (2005) -